
Mike Eby
Bioassay expert with several GxP bioassays on control systems at Genentech (see Poster and Patent sections). ... | South San Francisco, California, United States
*50 free lookup(s) per month.
No credit card required.
Mike Eby’s Emails mi****@23****.com
Mike Eby’s Phone Numbers No phone number available.
Social Media
Mike Eby’s Location South San Francisco, California, United States
Mike Eby’s Expertise Bioassay expert with several GxP bioassays on control systems at Genentech (see Poster and Patent sections). Currently working on target selection and validation of immune-related genes from 23andMe's GWAS/PheWAS data for early-stage drug development with an emphasis on making QC-ready bioassays and supporting orthogonal primary bioassays to for drug candidate selection. I most enjoy cell line engineering to generate QC-ready bioassays as early as possible not only to make better drugs for patients, but also to save time and money in development. Using crenezumab as an example of why earlier is better, I had been tasked with generating the regulatory-required bioassay for crenezumab while in Ph3 (see Patent section). With my assay, we discovered issues with new higher-yield lots of the late-stage drug that were NOT seen in the characterized/validated binding assays used through Ph2 -- Delaying generating the characterized/valdiated bioassay until Ph3 proved to be expensive and a waste of resources. ELISA assays are generally faster to validate, but they cannot address important relevant functional information (e.g. interaction w/ the plasma membrane, co-receptor interaction(s), hyperpotency of HMWS/LMWS impurities in DS/DP, etc). Had we had the assay in place in Ph1/2, we could have made a proper higher-yield biosimilar of our own drug... A well-made QC-ready reporter cell line is easy to use, captures a major mechanism of action and, ideally, should be well characterized in early stage research to enable consistency through commercialization. If possible, a well-characterized orthogonal primary cell-based assay should also be in place before Ph1. This is what I do for my inflammation and immunology projects at 23andMe.
Mike Eby’s Current Industry 23andme
Mike
Eby’s Prior Industry
University Of Washington
|
Ut Southwestern Medical Center
|
Genentech
|
23andme
Not the Mike Eby you were looking for?
Find accurate emails & phone numbers for over 700M professionals.
Work Experience

23andme
Sr. Scientist I (Therapeutics Discovery)
Mon Apr 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) — Present
23andme
Scientist II (Therapeutics Discovery)
Sun Oct 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) — Mon Apr 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
23andme
Scientist I (Therapeutics)
Wed Apr 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Sep 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
23andme
Senior Associate Scientist (Therapeutics)
Mon Jan 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) — Wed Apr 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Genentech
Senior Research Associate (Process Development)
Wed Jan 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) — Mon Jan 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Genentech
Research Associate (Research)
Fri Nov 01 2002 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Dec 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Ut Southwestern Medical Center
Research Associate
Sun Nov 01 1998 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Nov 01 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
University Of Washington
Research Technologist
Tue Apr 01 1997 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Nov 01 1998 00:00:00 GMT+0000 (Coordinated Universal Time)